Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer

被引：9

作者：

Jeanson, Arnaud

Boyer, Arnaud

Greillier, Laurent

Tomasini, Pascale

Barlesi, Fabrice

机构：

[1] Aix Marseille Univ, AP HM, Multidisciplinary Oncol & Therapeut Innovat Dept, Marseille, France

[2] Aix Marseille Univ, CNRS UMR7258, Inserm UMR1068,UM105, Predict Oncol Lab,Ctr Rech Cancerol Marseille, Marseille, France

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2019年 / 19卷 / 01期

关键词：

Trametinib; non-small cell lung cancer; Mitogen-activated protein kinase pathway; BRAF; KRAS; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; MEK INHIBITOR; PHASE-II; AZD6244; ARRY-142886; BRAF; MULTICENTER; DOCETAXEL; COMBINATION; GUIDELINE;

D O I：

10.1080/14737140.2019.1554440

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction:Mitogen-activated protein kinase (MAPK) pathway is known to be involved in the tumorigenesis of cancer cells including non-small cell lung cancer (NSCLC) and kinases involved in this pathway are frequently mutated. The development of new targeted therapies in cancer has led to the evaluation of MEK-inhibitors. Areas covered: This article reviews different studies using trametinib alone, in combination with other targeted therapies or associated with other non-targeted therapies in NSCLC, with a focus on KRAS mutant and BRAF mutant NSCLC. Expert commentary: Trametinib demonstrated activity in association with a BRAF inhibitor when BRAF was mutated. The combination of trametinib and dabrafenib has been approved for this population of BRAF mutant NSCLC patients. For KRAS mutant NSCLC, the combination of trametinib with chemotherapy has showed promising results and should be further assessed. Several clinical trials are ongoing, assessing trametinib in combination with other targeted therapies. In addition, preclinical studies suggest a synergistic effect of trametinib in combination with immune checkpoint inhibitors and such combinations should be studied in clinical trials.

引用

页码：11 / 17

页数：7

共 34 条

[11] Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition [J].

Hoeflich, Klaus P. ;

Merchant, Mark ;

Orr, Christine ;

Chan, Jocelyn ;

Den Otter, Doug ;

Berry, Leanne ;

Kasman, Ian ;

Koeppen, Hartmut ;

Rice, Ken ;

Yang, Nai-Ying ;

Engst, Stefan ;

Johnston, Stuart ;

Friedman, Lori S. ;

Belvin, Marcia .

CANCER RESEARCH, 2012, 72 (01) :210-219

[12] Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma [J].

Hu-Lieskovan, Siwen ;

Mok, Stephen ;

Moreno, Blanca Homet ;

Tsoi, Jennifer ;

Robert, Lidia ;

Goedert, Lucas ;

Pinheiro, Elaine M. ;

Koya, Richard C. ;

Graeber, Thomas G. ;

Comin-Anduix, Begona ;

Ribas, Antoni .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (279)

[13] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations [J].

Hyman, David M. ;

Puzanov, Igor ;

Subbiah, Vivek ;

Faris, Jason E. ;

Chau, Ian ;

Blay, Jean-Yves ;

Wolf, Juergen ;

Raje, Noopur S. ;

Diamond, Eli L. ;

Hollebecque, Antoine ;

Gervais, Radj ;

Elena Elez-Fernandez, Maria ;

Italiano, Antoine ;

Hofheinz, Ralf-Dieter ;

Hidalgo, Manuel ;

Chan, Emily ;

Schuler, Martin ;

Lasserre, Susan Frances ;

Makrutzki, Martina ;

Sirzen, Florin ;

Veronese, Maria Luisa ;

Tabernero, Josep ;

Baselga, Jose .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08) :726-736

[14] A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours [J].

Infante, Jeffrey R. ;

Papadopoulos, Kyriakos P. ;

Bendell, Johanna C. ;

Patnaik, Amita ;

Burris, Howard A., III ;

Rasco, Drew ;

Jones, Suzanne F. ;

Smith, Lon ;

Cox, Donna S. ;

Durante, Michael ;

Bellew, Kevin M. ;

Park, Joohyun ;

Le, Ngocdiep T. ;

Tolcher, Anthony W. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) :2077-2085

[15] Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study [J].

Jaenne, Pasi A. ;

Shaw, Alice T. ;

Pereira, Jose Rodrigues ;

Jeannin, Gaelle ;

Vansteenkiste, Johan ;

Barrios, Carlos ;

Franke, Fabio Andre ;

Grinsted, Lynda ;

Zazulina, Victoria ;

Smith, Paul ;

Smith, Ian ;

Crino, Lucio .

LANCET ONCOLOGY, 2013, 14 (01) :38-47

[16] Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial [J].

Janne, Pasi A. ;

van den Heuvel, Michel M. ;

Barlesi, Fabrice ;

Cobo, Manuel ;

Mazieres, Julien ;

Crino, Lucio ;

Orlov, Sergey ;

Blackhall, Fiona ;

Wolf, Juergen ;

Garrido, Pilar ;

Poltoratskiy, Artem ;

Mariani, Gabriella ;

Ghiorghiu, Dana ;

Kilgour, Elaine ;

Smith, Paul ;

Kohlmann, Alexander ;

Carlile, David J. ;

Lawrence, David ;

Bowen, Karin ;

Vansteenkiste, Johan .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18) :1844-1853

[17] Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer [J].

Joshi, Monika ;

Rice, Shawn J. ;

Liu, Xin ;

Miller, Bruce ;

Belani, Chandra P. .

PLOS ONE, 2015, 10 (02)

[18] MEK inhibitors under development for treatment of non-small-cell lung cancer [J].

Kim, Chul ;

Giaccone, Giuseppe .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) :17-30

[19] Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [J].

Lindeman, Neal I. ;

Cagle, Philip T. ;

Aisner, Dara L. ;

Arcila, Maria E. ;

Beasley, Mary Beth ;

Bernicker, Eric H. ;

Colasacco, Carol ;

Dacic, Sanja ;

Hirsch, Fred R. ;

Kerr, Keith ;

Kwiatkowski, David J. ;

Ladanyi, Marc ;

Nowak, Jan A. ;

Sholl, Lynette ;

Temple-Smolkin, Robyn ;

Solomon, Benjamin ;

Souter, Lesley H. ;

Thunnissen, Erik ;

Tsao, Ming S. ;

Ventura, Christina B. ;

Wynes, Murry W. ;

Yatabe, Yasushi .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (03) :323-358

[20] The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4 [J].

Liu, Li ;

Mayes, Patrick A. ;

Eastman, Stephen ;

Shi, Hong ;

Yadavilli, Sapna ;

Zhang, Tiandian ;

Yang, Jingsong ;

Seestaller-Wehr, Laura ;

Zhang, Shu-Yun ;

Hopson, Chris ;

Tsvetkov, Lyuben ;

Jing, Junping ;

Zhang, Shu ;

Smothers, James ;

Hoos, Axel .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1639-1651

← 1 2 3 4 →